eXmoor Pharma

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has announced a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS), the experts in cellular starting materials providing donor material solutions to the cell and gene therapy industry.

eXmoor Pharma, a full-service Cell and Gene Therapy (CGT) CDMO, has appointed Dr James Miskin as Non-Executive Director.

eXmoor Pharma has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub.

Our latest report demonstrates the real-world success and scalable manufacturing available in the UK’s globally competitive ecosystem.

Find out about how opposition parties are positioning themselves in an increasingly fragmented political landscape, and what it might mean for our sector now and in the long term.

eXmoor Pharma and UCL have launched a new partnership to strengthen the pathway from academic research to GMP delivery, giving UCL innovators earlier access to CMC expertise, development capabilities and clinical manufacturing support to accelerate the translation of cell and gene therapies.

BIA is pleased to announce the appointment of Lucy Foley, Chief Technology Officer at eXmoor Pharma, as Vice Chair of its Manufacturing Advisory Committee (MAC).

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing. Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scale. Virica and eXmoor will receive advisory services and funding through collaborative Canada-UK government program.

When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.  

Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma. The multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.

eXmoor’s Cell & Gene Therapy Centre can now offer a full range of GMP services for cell and gene therapies including manufacture, fill/finish, packaging, labelling, and shipping to global clinical sites